Catalyst Wire Dossier Catalyst Wire Dossier

YCANTH (VP-102/TO-208)

cantharidin · Verrica Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for YCANTH (VP-102/TO-208), covering 2026-03-09 to 2026-03-09. Get the full timeline:

Most recent: Clinical Trial Update: Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) [Phase 3]

See pricing